

Lyon, April 10th 2014 - The **MEDICREA** group (FR0004178572-ALMED), listed on Alternext Paris and eligible for *PEA-PME* SME equity savings plans, a company that specializes in the development of innovative surgical technologies for the treatment of spinal pathologies, announces its sales for its 1st quarter to March 31st 2014.

SALES – 1ST QUARTER OF 2014

In thousands of euros	Q1 2013	Q1 2014
Sales	5,376	5,405

Forex changes had a negative impact of 2% on 1st quarter 2014 sales growth

The Group has continued its development in the United States with sales up 18% in dollars in the 1st quarter of 2014 compared with the same period of 2013.

In France, over the quarter the Group recorded sales growth of close to 40% thanks to the extension of its product range and its referencing in new hospitals.

“We recorded an excellent month of March and strong growth in the United States and France. Nevertheless, our 1st quarter sales growth remained limited, weighed on by the import difficulties encountered by our leading distributor in Brazil and by the gradual upturn in activity in some European countries”, emphasizes Denys SOURNAC, Chairman and CEO of MEDICREA. “These issues have now been resolved and the visibility on our distributors’ order books has significantly improved. 2nd quarter sales should therefore see buoyant growth compared with the quarter that has just ended”, Denys SOURNAC added.

OUTLOOK

The strengthening of the sales teams in the United States and France, as well as the recent recruitments aimed at strengthening the international sales team, will see their full effects over the 2nd half of the year. Moreover, the Group is about to launch a major product innovation that should allow it to move up to the next level and accelerate its sales growth, primarily in the United States.

Next publication: Sales for the 1st half of 2014: July 10th 2014, after market.

The AGM will take place on June 25th at 10 am in the Company’s head offices.

PEA-PME eligibility

MEDICREA confirms its eligibility for the new *PEA-PME* SME equity savings plan setup in accordance with decree n°2014-283 of March 4th, 2014 published within the framework of the application of article 70 of the 2014 finance law n° 2013-1278 of December 29th, 2013 defining the conditions for companies to be eligible for *PEA-PME* SME savings plans: less than 5,000 staff, annual revenue of less than 1,500 million euros, total balance sheet of less than 2,000 million euros and autonomous as defined by CE 800/2008.

ABOUT MEDICREA (www.medicrea.com)

MEDICREA specializes in the design, development, manufacture and distribution of orthopedic implants dedicated to spinal surgery. In a \$10 billion market, MEDICREA is a very dynamic small to medium-sized business of 120 employees with unique innovation capabilities. The Company enjoys an excellent and ever-improving reputation and develops unique relationships with the most visionary and creative spine surgeons in France, the UK, and the USA. Products developed and patented by MEDICREA provide neurosurgeons and orthopedic surgeons specialized in the spine with new and less-invasive surgical solutions that are faster and easier to implement than traditional techniques. The Group’s headquarters are based near Lyon, France, and it also has a manufacturing facility for surgical instruments and implants located in La Rochelle as well as three distribution subsidiaries in the USA, the UK and France.

Contacts:

MEDICREA

Denys Sournac, Chairman and CEO
dsournac@medicrea.com
Fabrice Kilfiger, Chief Financial Officer
fkilfiger@medicrea.com
Tel: +33 (0)4 72 01 87 87

NewCap.

Financial Communication / Press & Investor Relations
Sophie Boulila / Pierre Laurent
Tel: +33 (0)1 44 71 94 91
medicrea@newcap.fr



MEDICREA is listed on ALTERNEXT Paris
ISIN: FR 0004178572 – Ticker: ALMED